Skip to main content
. 2009 Nov 17;115(13):2578–2585. doi: 10.1182/blood-2009-08-236471

Figure 2.

Figure 2

Waterfall plot of best responses in evaluable patients observed by cohort in the phase 2 study. Six subjects had greater than 100% increase in size of lesions; these values are listed at 100% for display purposes. Seventeen patients are not included because of early termination of drug because of toxicity or disease progression and no formal postscreening assessment.